October 2014 in “Journal of the Portuguese Society of Dermatology and Venereology” Early recognition and treatment of LPP can prevent hair loss and improve quality of life.
21 citations
,
August 2013 in “Journal of Dermatological Treatment” Low-level light therapy may help hair regrowth, but more research is needed.
15 citations
,
September 2018 in “Applied Biological Chemistry” Matrigel supports cell growth and repair, and thymosin beta 4 aids tissue regeneration and healing.
June 2025 in “Acta Dermato Venereologica” Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.
December 2018 in “Esperienze dermatologiche” A lotion with Centella asiatica extract reduced hair loss by 41% and increased hair strength without side effects.
6 citations
,
September 2018 in “Journal of Dermatological Treatment” LLLT devices for hair loss need more research to define proper guidelines.
4 citations
,
December 2020 in “Tissue Barriers” Loricrin affects skin immune function and homeostasis.
40 citations
,
January 1996 in “Journal of Dermatological Treatment” Antimicrobial lotion reduces inflammation and increases hair density in hair loss patients.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
Mesenchymal stem cells from laser-assisted liposuction are as effective and safe as those from conventional methods for cell therapy.
Low-level laser therapy may help with hair loss but needs more research.
January 2025 in “Biomedicines” High testosterone levels can harm fertility by disrupting the LIF signaling pathway in the uterus.
August 2020 in “OPAL (Open@LaTrobe) (La Trobe University)” July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
March 2025 in “Laboratory Investigation” Mesothelioma of the tunica vaginalis testis is rare, often high-grade, and has a median survival of about 24 months.
1 citations
,
January 2017 in “Journal of Clinical Trials & Patenting” The lotion safely and effectively reduces unwanted hair growth.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
MSC-CM cream speeds up burn wound healing better than the control treatment.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
3 citations
,
July 2025 in “International Immunopharmacology”
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
October 2022 in “The American journal of gastroenterology” Thymoma-associated multiorgan autoimmunity can cause liver damage and affects multiple organs, with limited treatment options and a generally poor prognosis.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
March 2022 in “Hair transplant forum international” Using a special laser and growth serum can safely increase hair thickness and density in people with hair loss.
May 2005 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Truncated LTBP-1 disrupts TGF-beta signaling, affecting hair growth.
January 2026 in “Dermatologic Therapy” Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.